Asad Haider
Stock Analyst at Goldman Sachs
(2.80)
# 1,961
Out of 5,090 analysts
13
Total ratings
80%
Success rate
17.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asad Haider
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NAMS NewAmsterdam Pharma Company | Maintains: Neutral | $30 → $37 | $35.97 | +2.86% | 2 | Dec 2, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $51 → $57 | $51.95 | +9.72% | 2 | Dec 2, 2025 | |
| JNJ Johnson & Johnson | Maintains: Buy | $186 → $212 | $202.48 | +4.70% | 2 | Oct 9, 2025 | |
| INVA Innoviva | Initiates: Sell | $17 | $20.76 | -18.11% | 1 | Sep 30, 2025 | |
| RPRX Royalty Pharma | Initiates: Buy | $42 | $39.17 | +7.24% | 1 | Sep 30, 2025 | |
| PCVX Vaxcyte | Initiates: Neutral | $38 | $46.28 | -17.88% | 1 | Sep 12, 2025 | |
| BNTX BioNTech SE | Initiates: Neutral | $110 | $95.99 | +14.60% | 1 | May 29, 2025 | |
| LLY Eli Lilly and Company | Upgrades: Buy | $892 → $888 | $1,014.49 | -12.47% | 1 | Apr 8, 2025 | |
| ABBV AbbVie | Assumes: Neutral | $194 | $228.71 | -15.18% | 1 | Apr 8, 2025 | |
| PFE Pfizer | Downgrades: Neutral | $32 → $25 | $25.70 | -2.72% | 1 | Apr 8, 2025 |
NewAmsterdam Pharma Company
Dec 2, 2025
Maintains: Neutral
Price Target: $30 → $37
Current: $35.97
Upside: +2.86%
Bristol-Myers Squibb Company
Dec 2, 2025
Maintains: Neutral
Price Target: $51 → $57
Current: $51.95
Upside: +9.72%
Johnson & Johnson
Oct 9, 2025
Maintains: Buy
Price Target: $186 → $212
Current: $202.48
Upside: +4.70%
Innoviva
Sep 30, 2025
Initiates: Sell
Price Target: $17
Current: $20.76
Upside: -18.11%
Royalty Pharma
Sep 30, 2025
Initiates: Buy
Price Target: $42
Current: $39.17
Upside: +7.24%
Vaxcyte
Sep 12, 2025
Initiates: Neutral
Price Target: $38
Current: $46.28
Upside: -17.88%
BioNTech SE
May 29, 2025
Initiates: Neutral
Price Target: $110
Current: $95.99
Upside: +14.60%
Eli Lilly and Company
Apr 8, 2025
Upgrades: Buy
Price Target: $892 → $888
Current: $1,014.49
Upside: -12.47%
AbbVie
Apr 8, 2025
Assumes: Neutral
Price Target: $194
Current: $228.71
Upside: -15.18%
Pfizer
Apr 8, 2025
Downgrades: Neutral
Price Target: $32 → $25
Current: $25.70
Upside: -2.72%